{"id":2264,"date":"2026-06-10T19:00:00","date_gmt":"2026-06-10T22:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2264"},"modified":"2026-06-10T19:00:00","modified_gmt":"2026-06-10T22:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-colorretal-direito-d3-cme-lateral-watch-and-wait","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-colorretal-direito-d3-cme-lateral-watch-and-wait\/","title":{"rendered":"PGRSS colorretal D: D3, CME, lateral, W&W"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica colorretal direito que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica colorretal direito<\/strong> + CRC carcinoma colorretal direito ceco+ascendente+transverso 35%<\/strong> + D3 lymph node dissection D1+D2+D3 padr\u00e3o Jap\u00e3o<\/strong> + CME Complete Mesocolic Excision Hohenberger Erlangen princ\u00edpio<\/strong> + CVL central vascular ligation<\/strong> + HIPEC Hyperthermic Intraperitoneal Chemotherapy peritoneal carcinomatosis Sugarbaker PRODIGE 7<\/strong> + TaTME+ESD endoscopic + RAPIDO+PRODIGE 23 TNT total neoadjuvant<\/strong> + FOLFIRINOX+FOLFOX+CAPOX+pembrolizumab MSI-H+nivolumab+ipilimumab+regorafenib+TAS-102 trifluridine+cetuximab+panitumumab+bevacizumab+sotorasib KRAS-G12C+adagrasib KRAS+tucatinib HER2+larotrectinib NTRK+selpercatinib RET+dabrafenib+trametinib BRAF V600E<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (CRC direito ceco+ascendente+transverso + adenoCa intestinal + GIST + carcinoide + linfoma + Lynch HNPCC + FAP) + Grupo A4 (linfa D1 parac\u00f3lica + D2 intermedi\u00e1ria + D3 central + CME mesoc\u00f3lica + linfa apical + para-a\u00f3rtica) + Grupo C (Y-90 SIRT met\u00e1stase hep\u00e1tica + Iridium-192 brachy raro + Ra-223 met\u00e1stase \u00f3ssea raro) + Grupo E (perfuro bi\u00f3psia colonoscopia + agulha core US\/CT-guided + ESD endoscopic submucosal dissection) + Lista C5 (FOLFOX+FOLFIRINOX+CAPOX+IROX+pembrolizumab Keytruda KEYNOTE-177 MSI-H 1L+nivolumab Opdivo CheckMate-8HW+ipilimumab Yervoy+regorafenib Stivarga 3L CORRECT+TAS-102 trifluridine\/tipiracil Lonsurf RECOURSE+cetuximab Erbitux EGFR RAS-WT+panitumumab Vectibix+bevacizumab Avastin+sotorasib Lumakras KRAS-G12C+adagrasib Krazati+tucatinib Tukysa HER2+larotrectinib Vitrakvi+entrectinib Rozlytrek NTRK+selpercatinib Retevmo RET+dabrafenib+trametinib BEACON BRAF V600E+encorafenib Braftovi+binimetinib Mektovi). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + CME D3<\/strong> + subdimensionam Lista C5 imuno+targeted<\/strong> + perdem rastreabilidade tumor colorretal<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS colorretal direito opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (CRC direito 35% + adenoCa + GIST + carcinoide + linfoma), A4 (CME D3 Hohenberger + CVL + apical), C (Y-90 SIRT + Iridium-192 + HIPEC), E (colonoscopia + ESD + RFA + microwave), Lista C5 (FOLFOX+FOLFIRINOX+pembrolizumab MSI-H+cetuximab+bevacizumab+sotorasib KRAS+tucatinib HER2+selpercatinib RET).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica colorretal direito, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos colorretal direito<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS colorretal direito tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 CRC direito+adenoCa<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCeco+ascend+transv<\/td>\n<\/tr>\n
A4 CME D3 Hohenberger<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCVL+apical+25-40 LN<\/td>\n<\/tr>\n
C Y-90+HIPEC<\/td>\n0,8-2,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nSIRT+Sugarbaker+CNEN<\/td>\n<\/tr>\n
E colonoscopia+ESD+RFA<\/td>\n0,5-1,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOlympus+Erbe+Cool-Tip<\/td>\n<\/tr>\n
Lista C5 imuno+targeted<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nKEYNOTE-177+BEACON<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,8-33,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica colorretal direito m\u00e9dia porte.<\/p>\n

A1 CRC direito ceco+ascendente+transverso + Lynch + FAP: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS colorretal direito \u00e9 A1. Padr\u00e3o setorial inclui (a) CRC direito 35% colon ceco+ascendente+transverso at\u00e9 2\/3 distal<\/strong> com diferen\u00e7as biol\u00f3gicas vs esquerdo + frequente MSI-H+BRAF V600E+CIMP CpG island methylator phenotype+RAS wildtype+HER2 amplification + idade avan\u00e7ada+anemia+les\u00e3o fungoide volumosa; (b) adenoCa colorretal histologia<\/strong> com tubular+viloso+tubuloviloso+mucinoso+anel sinete+sertral+medular+adenoescamoso + grade well\/moderate\/poor differentiated + LVI lymphovascular invasion + PNI perineural invasion; (c) s\u00edndromes heredit\u00e1rias<\/strong> com Lynch HNPCC MMR-deficiente MLH1+MSH2+MSH6+PMS2+EPCAM + FAP familial adenomatous polyposis APC + MUTYH-associated MAP + Peutz-Jeghers STK11 + JPS BMPR1A\/SMAD4; (d) outros tumores<\/strong> GIST KIT+PDGFRA + carcinoide ileal + apendicite carcinoide + linfoma MALT colon + sarcoma intestinal + melanoma anal raro; (e) estadiamento TNM 8\u00aa + biomarker<\/strong> CEA + CA 19-9 + RAS+BRAF+MSI+HER2+NTRK+RET+TMB tumor mutational burden + CID C18 + Lynch testing universal screening 2022.<\/p>\n

Cl\u00ednica com A1 CRC direito madura garante margem R0<\/strong> + previne recidiva regional<\/strong> + otimiza estadiamento TNM+biomarker comprehensive<\/strong>. Como discutimos no post sobre retal baixa<\/a>, A1 colorretal \u00e9 base.<\/p>\n

A4 CME Complete Mesocolic Excision + D3 + CVL + colectomia direita estendida: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) CME Complete Mesocolic Excision Hohenberger Erlangen 2009<\/strong> com princ\u00edpio an\u00e1logo TME total mesorectal excision + plano embriol\u00f3gico mesocolon parietal vs visceral + sharp dissection + sp\u00e9cimen intacto; (b) D3 lymph node dissection padr\u00e3o Jap\u00e3o<\/strong> D1 parac\u00f3lica n\u00edvel 1 + D2 intermedi\u00e1ria n\u00edvel 2 + D3 central n\u00edvel 3 origem AMS+veia mesent\u00e9rica superior + 25-40 LN dissecados + Hashiguchi+Watanabe Japan; (c) CVL Central Vascular Ligation<\/strong> com ligadura origem AMS+VMS+veia ileoc\u00f3lica+c\u00f3lica direita+c\u00f3lica m\u00e9dia + alta vs baixa ligation + sobrevida CME+CVL prolongada; (d) colectomia direita<\/strong> com hemicolectomia direita standard + estendida transverso m\u00e9dio + ileohemicolectomia + intracorp\u00f3rea anastomose laparosc\u00f3pica\/rob\u00f3tica Da Vinci Xi + RAMIE colectomia; (e) colectomia direita laparosc\u00f3pica<\/strong> SILS Single Incision Laparoscopic Surgery + NOTES Natural Orifice Transluminal Endoscopic Surgery + rob\u00f3tica + ICG indocyanine green angiografia + perfus\u00e3o anastomose Spy-Plus.<\/p>\n

Cl\u00ednica com A4 CME+D3+CVL madura escala R0 90+%<\/strong> + escala 25-40 LN dissecados padr\u00e3o ouro<\/strong> + previne f\u00edstula anastom\u00f3tica 3-8%<\/strong>. Conex\u00e3o com retal baixa<\/a>.<\/p>\n

HIPEC Sugarbaker + Y-90 SIRT + ESD + watch-and-wait + KEYNOTE-177 + BEACON BRAF: o est\u00e1gio multimodal<\/h2>\n

A terceira camada \u00e9 HIPEC+Y-90+W&W+sist\u00eamico. Padr\u00e3o setorial inclui (a) HIPEC Hyperthermic Intraperitoneal Chemotherapy<\/strong> Sugarbaker 1995 + CRS Cytoreductive Surgery + PCI Peritoneal Cancer Index + CC Completeness Cytoreduction CC0\/CC1\/CC2\/CC3 + 41-43\u00b0C 30-90 min + mitomicina C+oxaliplatina+cisplatina + PRODIGE 7 colorretal negativo no overall; (b) PIPAC Pressurized IntraPeritoneal Aerosol Chemotherapy<\/strong> com Capnopen + minimally invasive aerosol + cisplatina+doxorrubicina+oxaliplatina + ascite refrat\u00e1ria paliativo; (c) Y-90 SIRT met\u00e1stase hep\u00e1tica colorretal<\/strong> SIR-Spheres Sirtex + TheraSphere Boston Scientific + EPOCH+SIRFLOX+FOXFIRE 1L colorretal liver-only + R$ 35-65k dose; (d) watch-and-wait W&W retal cCR p\u00f3s-TNT<\/strong> + RAPIDO TNT total neoadjuvant + PRODIGE 23 + IWWD International Watch and Wait Database + observa\u00e7\u00e3o retal cCR sem cirurgia salvage; (e) sist\u00eamico colorretal<\/strong> FOLFOX+FOLFIRINOX+CAPOX 1L + pembrolizumab Keytruda KEYNOTE-177 MSI-H 1L PFS 16,5m vs 8,2m FOLFOX HR 0,60 + nivolumab Opdivo CheckMate-8HW MSI-H 1L+ipilimumab Yervoy + cetuximab Erbitux+panitumumab Vectibix EGFR RAS-WT esquerdo + bevacizumab Avastin VEGF + sotorasib Lumakras+adagrasib Krazati KRAS-G12C 3L+ + tucatinib Tukysa+trastuzumab MOUNTAINEER HER2 3L + larotrectinib+entrectinib NTRK + selpercatinib RET + BEACON CRC encorafenib Braftovi+cetuximab BRAF V600E 2L + regorafenib Stivarga 3L CORRECT+TAS-102 Lonsurf 3L RECOURSE Lista C5.<\/p>\n

Cl\u00ednica com HIPEC+Y-90+W&W+sist\u00eamico madura escala HIPEC OS sustain Sugarbaker<\/strong> + escala KEYNOTE-177 MSI-H PFS 16,5m<\/strong> + escala BEACON BRAF V600E OS 9,3m<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade colorretal direito<\/h2>\n

Cl\u00ednica colorretal s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+C+E+sist\u00eamico.<\/p>\n

Cl\u00ednica colorretal A1 + A4 + FOLFOX.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + sist\u00eamico padr\u00e3o.<\/p>\n

Cl\u00ednica colorretal 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa colorretal + CME+D3 Hohenberger + KEYNOTE-177 MSI-H PFS 16,5m + BEACON BRAF.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica colorretal direito<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 imuno+targeted CRC<\/strong>. Sem segrega\u00e7\u00e3o FOLFOX+FOLFIRINOX+pembrolizumab+nivolumab+ipilimumab+cetuximab+panitumumab+bevacizumab+sotorasib+adagrasib+tucatinib+larotrectinib+selpercatinib+encorafenib+binimetinib+regorafenib+TAS-102 + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 CRC direito + esquerdo + retal<\/strong>. Confunde rastreabilidade lateralidade + impossibilita CME D3 vs LPLND + risco indica\u00e7\u00e3o inadequada (KRAS-WT esquerdo cetuximab vs MSI-H direito pembro vs BRAF V600E BEACON).<\/p>\n

O terceiro \u00e9 a falta de protocolo MSI\/MMR + RAS+BRAF + HER2 + NTRK testing universal<\/strong>. Sem Lynch testing universal screening + comprehensive biomarker panel + FoundationOne CDx+Guardant360 + tumor mutational burden = perda elegibilidade targeted+imuno + zero precision medicine.<\/p>\n

A regula\u00e7\u00e3o de PGRSS colorretal direito no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Colorretal<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS colorretal direito 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 CRC direito 35% ceco+ascendente+transverso+MSI-H+BRAF V600E+CIMP+RAS-WT+HER2 amplification+adenoCa tubular+viloso+mucinoso+anel sinete+Lynch HNPCC MLH1+MSH2+MSH6+PMS2+EPCAM+FAP APC+MUTYH MAP+Peutz-Jeghers+JPS+CEA+CA 19-9+TMB+CID C18+TNM 8\u00aa, A4 CME Hohenberger Erlangen 2009+D3 lymph node dissection padr\u00e3o Jap\u00e3o Hashiguchi+Watanabe+CVL Central Vascular Ligation AMS+VMS+25-40 LN+colectomia direita standard+estendida+ileohemicolectomia+laparosc\u00f3pica SILS+NOTES+rob\u00f3tica Da Vinci Xi+RAMIE+ICG Spy-Plus perfus\u00e3o, C HIPEC Sugarbaker 1995+CRS+PCI+CC0\/1\/2\/3+41-43\u00b0C+mitomicina+oxaliplatina+cisplatina+PRODIGE 7+PIPAC Capnopen+Y-90 SIR-Spheres Sirtex+TheraSphere Boston EPOCH+SIRFLOX+FOXFIRE+CNEN-NN-3.05, E colonoscopia Olympus EVIS X1+Pentax+ESD Olympus EndoCut+Erbe VIO 300D+IT-knife+Hook-knife+Dual-knife+RFA Boston Cool-Tip+microwave Emprint, Lista C5 FOLFOX+FOLFIRINOX+CAPOX+pembrolizumab Keytruda KEYNOTE-177 MSI-H 1L PFS 16,5m+nivolumab Opdivo CheckMate-8HW+ipilimumab+cetuximab Erbitux EGFR RAS-WT+panitumumab Vectibix+bevacizumab Avastin+sotorasib Lumakras+adagrasib Krazati KRAS-G12C+tucatinib Tukysa+trastuzumab MOUNTAINEER HER2+larotrectinib Vitrakvi+entrectinib Rozlytrek NTRK+selpercatinib Retevmo RET+BEACON encorafenib Braftovi+cetuximab BRAF V600E 2L OS 9,3m+regorafenib Stivarga CORRECT 3L+TAS-102 trifluridine\/tipiracil Lonsurf RECOURSE 3L+watch-and-wait W&W+RAPIDO+PRODIGE 23 TNT+IWWD International Watch Wait Database.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS colorretal direito: D3 + CME + lateral + watch-and-wait. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2263,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,1532,2773,3100],"class_list":["post-2264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-cme","tag-colorretal","tag-watch-and-wait"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2264"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2264\/revisions"}],"predecessor-version":[{"id":4355,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2264\/revisions\/4355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2263"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}